JB Pharma acquires leading brand of Rosuvastatin- Razel and combinations

New Delhi: Leading brand of Rosuvastatin, Razel will now be offered from JB Pharma as the company has now entered into an agreement with Glenmark Pharmaceuticals Ltd., to acquire the entire Razel (Rosuvastatin) franchise for the India and Nepal region.

With this acquisition, JB Pharma will now be the 8th-ranked company in the cardiology market, as Razel ranks among the top 10 brands in the Rosuvastatin molecule category in the country. These brands are focused on the cardiac segment in India and Nepal with a total covered market size of INR 2,444 crores as per the IQVIA MAT Oct '22 numbers.

Commenting on the acquisition, Mr. Nikhil Chopra, CEO & Whole Time Director, JB Pharma said, "We are glad to announce the acquisition of the Razel (Rosuvastatin & combinations) franchise, thereby marking JB's expansion into Statins, which is the largest therapeutic segment in cardiology. With this addition, we now have established a strong position in statins besides being among the leaders in Hypertension and Heart failure – all the fastest growing therapeutic indications in cardiology."

He further added, "We see good growth potential from the acquired brands. This acquisition will help us leverage our existing Go-To-Market model focussed for this segment and further strengthen our chronic portfolio."

J.B. Pharma, established in 1976, is one of the fastest-growing pharmaceutical companies in India and a leading player in hypertension and the heart failure segment. Besides its strong India presence, which accounts for majority of its revenue, its other two home markets are Russia and South Africa. In India, the company has five brands among the top 300 IPM brands in the country. The company exports its finished formulations to over 40 countries including the USA. Besides supplying branded generic formulations to several countries, it is also a leader in the manufacturing of medicated lozenges. The company ranks among the top 5 manufacturers globally in medicated and herbal lozenges. It has seven state-of-the-art manufacturing facilities in India including a dedicated manufacturing facility for lozenges. The manufacturing facilities are certified by leading regulators across the world.

Disclaimer: This post has been published under MD Brand Connect Initiative and is sponsored by JB Pharma.